Bioventus Q2 FY26 GAAP EPS rises to $0.47; revenue increases 4% to $153.2 million
BVS•Q2 results and profitability improve
Bioventus posted Q2 revenue of $153.2 million, up 4% from a year earlier.
- GAAP diluted EPS more than doubled to $0.47, helped by removal of a $24.6 million deferred-tax valuation allowance.
- Non-GAAP diluted EPS edged up 5% to $0.22.
- Adjusted EBITDA rose 4% to $35.3 million.
Cash flow, debt reduction and strategic review
Cash from operations totaled $19.9 million.
During the quarter, the company made a $20 million discretionary term-loan principal prepayment.
The board initiated a strategic alternatives review after receiving an unsolicited acquisition proposal, and 2026 guidance was reaffirmed.
